Comparing a New Dye With Standard Dye for Eye Blood Vessel Imaging
Tests the new dye MB-102 against standard dye in adults with eye diseases.
Plain-language title generated from the registry record
Registry title: Feasibility and Safety of MB-102 in Ocular Angiography as Compared to Fluorescein Sodium
Key facts
- Where
- Ann Arbor, United StatesSee the site
- Phase
- Early phase 1
Where in United States
- University of Michigan Kellogg Eye CenterAnn Arbor, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- MediBeacon
- Trial code
- NCT04008121
- Record updated
- 4 February 2026
- Original description
The objective of this study is to evaluate the safety and image quality of the investigational dye, MB-102, compared to the control dye (fluorescein sodium) in healthy and diseased eyes using fluorescent angiography for retinal vascular disease diagnosis and monitoring.Read full original descriptionShow less
A Pilot Study to Assess the Feasibility and Safety of MB-102 in Ocular Angiography as Compared to Fluorescein Sodium
The objective of this study is to evaluate the safety and image quality of the investigational dye, MB-102, compared to the control dye (fluorescein sodium) in healthy and diseased eyes using fluorescent angiography for retinal vascular disease diagnosis and monitoring.
Inclusion: Age > 18 years - male or female; Eligible female non-pregnant participants who are either not of child-bearing potential or willing to utilize adequate contraception during the trial; Males must be willing to practice abstinence or utilize adequate contraception from MB-102 dosing day to at least 7 days post dose; Participants willing to comply with study requirements; Participants who have signed an informed consent form; At least 5 participants will have a current history of retinal or choroidal vascular diseases.
Exclusion: Prior history of seizures; Prior enrollment and dosing in this study; History of drug or alcohol abuse within the past year; Current visually significant cataracts or other ophthalmic conditions that would limit appropriate collection of fundus photographs; Any characteristics which, in the opinion of the investigator, makes the participant a poor candidate for participation in the clinical trial (e.g. unstable medical condition including cardiovascular disease, or other conditions considered clinically significant or unstable by the Principal Investigator); History of severe allergic hypersensitivity reactions (unacceptable adverse events) or anaphylactoid reaction to any allergen including drugs, MB-102 and fluorescein sodium or other related products (intolerance to a drug is not considered a drug allergy); Women who are pregnant, lactating or planning to become pregnant during the study, or women who are of childbearing potential unwilling to utilize adequate contraception; Participation in another interventional trial within 30 days of treatment or concurrently enrolled in any other medical research study which could impact the results of the study; Site personnel immediately associated with the study or their immediate family members; Unable to tolerate ophthalmologic imaging.